Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Poster: AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results

Naval Daver,Paresh Vyas,Suman Kambhampati,Monzr Al Malki,Richard Larson,Adam Asch,Gabriel Mannis,Wanxing Chai-Ho,Tiffany Tanaka,Terrence Bradley,Deepa Jeyakumar,Eunice Wang,Guan Xing,Mark Chao,Giri Ramsingh,Camille Renard,Indu Lal,Joshua Zeidner,David Sallman

Clinical Lymphoma Myeloma and Leukemia（2022）

Cited 2|Views22
No score
Abstract
Magrolimab+azacitidine showed durable responses and encouraging overall survival in frontline patients with TP53-mutated AML unsuitable for intensive chemotherapy. A Ph3 trial of magrolimab+azacitidine vs standard-of-care in TP53-mutated AML (ENHANCE-2; NCT04778397) is ongoing.
More
Translated text
Key words
AML,acute myeloid leukemia,magrolimab,azacitidine,CD47,TP53, Phase I
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined